Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBV152A
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**BBV152A** is an investigational whole-virion, beta-propiolactone-inactivated SARS-CoV-2 vaccine formulation developed by Bharat Biotech with the Indian Council of Medical Research and the National Institute of Virology. It contains 3 micrograms of inactivated SARS-CoV-2 strain NIV-2020-770 antigen produced in Vero cells and adjuvanted with Algel-IMDG, an aluminum hydroxide gel formulation containing an imidazoquinoline TLR7/8 agonist. BBV152A was evaluated in phase 1 and phase 2 studies for prevention of COVID-19. It is distinct from the marketed BBV152 formulation sold as Covaxin, which used the 6 microgram Algel-IMDG formulation.
- Brand names
- COVAXIN
- Other names
- BBV152BBV-152BBV 152
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on BBV152A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBV152A.